SCHEDULE 13G: Tang Capital Group Discloses 5.3% Passive Stake in Spyre Therapeutics

Tang Capital Management, Kevin Tang, and affiliated entities have disclosed a passive 5.3% beneficial ownership stake in Spyre Therapeutics, Inc., totaling 3,200,000 shares of common stock.

Summary

• The filing reports that Tang Capital Management, LLC, Kevin Tang, Tang Capital Partners, LP, Tang Capital Partners International, LP, Tang Capital Partners III, Inc., and Tang Capital Partners IV, Inc. collectively hold a beneficial ownership stake in Spyre Therapeutics, Inc.
• The group beneficially owns an aggregate of 3,200,000 shares of Spyre Therapeutics' Common Stock.
• This ownership represents 5.3% of the outstanding Common Stock of Spyre Therapeutics, Inc.
• The percentage is calculated based on 60,275,561 shares of Common Stock outstanding as of April 4, 2025, as reported in the Issuer's Proxy Statement filed on April 14, 2025.
• The reporting persons share both voting and dispositive power over the 3,200,000 shares.
• The acquisition of these securities was not for the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 6

Explanation: The document is a factual regulatory filing disclosing a passive ownership stake. While not explicitly positive or negative, the disclosure of a significant stake by an institutional investor like Tang Capital can be viewed as a neutral to slightly positive signal of confidence in the company.

Positives

• A notable investment group, Tang Capital, has disclosed a significant passive stake (5.3%) in Spyre Therapeutics, which could be interpreted by the market as a vote of confidence in the company.

Future Outlook

The document, a Schedule 13G, is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding Spyre Therapeutics' future performance or strategic direction.

Management Comments

• The reporting persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Spyre Therapeutics, Inc., and were not acquired or held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing is a standard regulatory disclosure of a significant passive ownership stake by an investment group in a publicly traded company. It does not provide specific industry trends or competitive analysis.

Corporate Governance

Related Party Transactions

• The filing details the relationships among the reporting persons, including Tang Capital Management, LLC as the general partner of Tang Capital Partners, LP and Tang Capital Partners International, LP, and Kevin Tang as the manager of Tang Capital Management, LLC and CEO of Tang Capital Partners III, Inc. and Tang Capital Partners IV, Inc., indicating a coordinated group filing.

Stakeholder Impact

• Shareholders will be informed of a new significant institutional investor holding a 5.3% stake in the company, potentially influencing market perception and trading activity.

Key Dates

Keywords

Spyre Therapeutics, Tang Capital Management, Kevin Tang, Schedule 13G, beneficial ownership, common stock, institutional investment, passive stake, SEC filing